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Retinitis pigmentosa (RP) is a rare, progressive disease that affects photoreceptors and
retinal pigment epithelial (RPE) cells with blindness as a final outcome. Despite high
medical and social impact, there is currently no therapeutic options to slow down the
progression of or cure the disease. The development of effective therapies was largely
hindered by high genetic heterogeneity, inaccessible disease tissue, and unfaithful model
organisms. The fact that components of ubiquitously expressed splicing factors lead to
the retina-specific disease is an additional intriguing question. Herein, we sought to
correlate the retinal cell-type-specific disease phenotype with the splicing profile shown
by a patient with autosomal recessive RP, caused by a mutation in pre-mRNA splicing
factor 8 (PRPF8). In order to get insight into the role of PRPF8 in homeostasis and
disease, we capitalize on the ability to generate patient-specific RPE cells and reveal
differentially expressed genes unique to RPE cells. We found that spliceosomal complex
and ribosomal functions are crucial in determining cell-type specificity through differential
expression and alternative splicing (AS) and that PRPF8 mutation causes global changes
in splice site selection and exon inclusion that particularly affect genes involved in these
cellular functions. This finding corroborates the hypothesis that retinal tissue identity is
conferred by a specific splicing program and identifies retinal AS events as a framework
toward the design of novel therapeutic opportunities.
Keywords: iPSC, RPE, RNA-Seq, retinitis pigmentosa, pre-mRNA splicing, alternative splicing, PRPF8
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INTRODUCTION
Retinitis pigmentosa (RP), the most common form of hereditary
retinal dystrophies, is a progressive blinding disease that
currently lacks effective therapies (Hartong et al., 2006).
Typically, light-sensing photoreceptors and the underlying
retinal pigment epithelium (RPE), responsible for photoreceptor
homeostasis, are the primary degenerated cells. RP is highly
genetically heterogeneous with over 80 disease-causing genes
identified to date1. Mutations in splicing proteins are described to
account altogether as a second most common cause of autosomal
dominant RP (adRP) (Sullivan et al., 2006).
Splicing reaction is a process of excision of non-coding
intervening sequences, introns, and exon ligations resulting in
coding capacity diversification of a limited number of expressed
genes with > 90% of 20,000 human protein-coding genes
producing multiple mRNA isoforms. This stepwise reaction is
performed by spliceosome, a multisubunit ribonucleoprotein
complex with the core components uridine-rich small non-
coding nuclear RNAs (snRNAs, U1, U2, U4, U5, and U6) and
associated proteins that assemble on pre-mRNA to catalyze the
excision of introns (Wahl et al., 2009). Mutations in seven
genes coding for pre-mRNA processing factors known as PRPFs
(PRPF8, PRPF31, PRPF3, PRPF4, and PRPF6), SNRNP200, and
PAP-1 have been described to cause adRP (Sullivan et al., 2006).
While these genes are expressed ubiquitously in all tissues and
are highly conserved among eukaryotes, it remains unclear why
mutations thereof exhibit exclusively retinal phenotype. It has
been proposed that PRPF mutations might cause global splicing
dysregulation and affects only retina because of retinal enhanced
splicing activity (Tanackovic et al., 2011). Alternatively, a retina-
specific splicing code could confer tissue-specific transcripts
that are altered by mutations in splicing factors and therefore
cause the disease.
PRPF8 is a 220-kDa, evolutionary highly conserved protein
described to play a central role in spliceosomal catalytic activity
(Grainger and Beggs, 2005; Galej et al., 2013). Mutations in
the C-terminal tail have been described to cause adRP (RP13,
OMIM600059) (McKie et al., 2001) while mutations in the
N-terminal part have recently been found in glaucoma patients.
Mutations in PRPF8, unlike PRPF31, show in the majority of
cases complete penetrance, with marked disease progression,
exhibiting moderate phenotype with residual vision up to their
fifth decade or severe clinical phenotypes initiating in the first
decade of life (Martinez-Gimeno et al., 2003; Maubaret et al.,
2011; Escher et al., 2018). The degree of severity is proposed to
be related to the type of mutation (Escher et al., 2018). Mouse
models, Prpf8-H2309P with knocked-in missense mutation,
showed only mild phenotype in RPE ultrastructure only at
2 years of age, without any loss of ERG signal (Graziotto et al.,
2011). Therefore, these animal models are insufficient and human
models that recapitulate the clinical phenotype are required to
decipher the mechanism of disease.
Native human retina is a largely inaccessible tissue that
cannot provide enough research material. Moreover, it is non-
expandable due to its postmitotic state. The generation of
1http://www.sph.uth.tmc.edu/retnet
induced pluripotent stem cells (iPSCs) from accessible tissue
like patient’s skin, and coaxing them toward retinal tissue, offers
an unprecedented opportunity to study the disease and also
find new therapies. Moreover, the advantage of the iPSC-based
models is that they recapitulate the disease-causing mutation
and patient’s genetic complexity, essential for complex and
late-onset diseases. The iPSCs can be directed toward both
photoreceptors and RPE cells, capturing their morphology and
function (Hirami et al., 2009; Reichman et al., 2014; Zhong
et al., 2014) and have been used successfully in disease modeling
(Lukovic et al., 2015, 2020; Shimada et al., 2017; Buskin et al.,
2018). The identification of primary affected cell type in RP is
hampered due to strong interplay between photoreceptor and
RPE cells; namely, mutations of genes expressed in RPE lead
to secondary photoreceptor degeneration; conversely, mutations
in genes expressed in photoreceptors induce collateral RPE
disruptions. This task is additionally obscured in PRPF-caused
RP owing to their ubiquitous nature. Recent studies support RPE
as likely primary affected cell type by PRPF mutations. Mouse
models Prpf3-T49M, Prpf8-H2309P and Prpf31+/− showed
moderate ultrastructural alterations including loss of basal
infoldings, accumulation of amorphous deposits beneath the
RPE and presence of vacuoles while neural retina remained
intact (Graziotto et al., 2011). These morphological alterations
observed in old mice are preceded by functional disruption
in phagocytosis of photoreceptor outer segments (POS) and
altered adhesion between RPE microvilli and photoreceptors
10 days upon birth (Farkas et al., 2014). Finally, in PRPF31-RP
patient-derived photoreceptors and RPE, both cell types were
altered, however; iPSC-RPE were most severely affected with
ultrastructural and functional abnormalities. Furthermore, this
study showed that spliceosome global dysregulation underlies
disrupted RPE polarity, trans-epithelial resistance, phagocytosis,
primary cilia length, and incidence in human and mouse
genetic background (Buskin et al., 2018). The aforementioned
studies prompted us to study PRPF8 pathomechanism in a cell-
autonomous manner in patient-derived RPE cells.
Herein, we have generated RPE cells from reprogrammed
dermal skin fibroblasts derived from a patient diagnosed
with adRP and bearing a pathogenic mutation in PRPF8
(NM_006445:c.6974_6994del) (Lukovic et al., 2017) in a
heterozygous state (from here on: Patient-RPE) and patient’s
non-affected tissue, i.e., fibroblasts (from here on: Patient-
fibroblasts). An unrelated, non-affected individual was used as
control (from here on: Control-RPE and Control-fibroblasts).
We generated RNA sequencing (RNA-Seq) data for three
independent experimental replicates per sample and performed
a whole-transcriptome analysis where healthy control samples
were compared to mutation-bearing cells, in order to depict
retinal-specific transcriptional signature caused by the mutation.
MATERIALS AND METHODS
Human Subjects
Research procedures followed the principles of the Declaration
of Helsinki. The study was approved by the Research Ethical
Committee of the Hospital of Terrassa and Valencian Ethics
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Committee CAEC (Comité Etico Autonomico de Estudios
Clínicos), Valencia, Spain. Both subjects provided written
informed consent after the nature of the study procedures had
been fully explained.
adRP Patient’s Clinical Phenotype
The patient reported a history of nyctalopia starting from the
first decade of life. At the age of 20 the best-corrected visual
acuity (BCVA) was 20/40 in the right eye and 20/30 in the left
eye. Anterior segment examination showed minimal posterior
subcapsular cataract in the right eye, being normal in the
left eye. Fundus examination showed the typical RP changes,
consisting in optic disk pallor, retinal vessel attenuation, and
extensive bone spicule-like pigmentation extending from the
vascular arcades toward the periphery. No abnormalities at
the macula were detected. Humphrey visual field examination
showed a severe visual field loss, with 10◦ central preserved and
a peripheral remnant in the left eye. Electroretinography was
abolished at that time.
At the age of 47, lens surgery had been performed in the right
eye, so that BCVA was 20/40. In the right eye, she presented a
moderate subcapsular cataract, being the BCVA 20/70. Fundus
examination showed the typical RP changes. Spectral domain
optical coherence tomography showed a complete absence of
outer retinal bands corresponding to photoreceptors. Macular
edema or epiretinal membrane was not detected in any
moment of evolution.
Cell Line Derivation and Differentiation
Fibroblast Cell Culture
Cryopreserved fibroblast cell lines derived from skin biopsies
from the female RP patient (Patient-fibroblasts) and a healthy
(BCVA40/40) man (Control-fibroblasts) were thawed and
cultured in DMEM (10% FBS, 2 mM GlutaMAX, 50 U/ml
penicillin and 50 mg/ml streptomycin) at 37◦C under 5% CO2.
Fibroblasts at passages 6–8 were used in this study. Samples
were collected in triplicates, from independent cell cultures.
Authentication of the fibroblast cell lines by microsatellite STR
markers was performed to confirm the identity to the iPSC lines.
iPSC Cell Culture and Differentiation Toward RPE
Two iPSC lines were employed in this study (Supplementary
Table 4). The iPSC line derived from the patient, clinically
diagnosed with RP and molecularly genotyped previously,
by reprogramming dermal fibroblasts using a non-integrative
Sendai virus (Lukovic et al., 2017) has been employed. As
control cell line, iPSC Ctrl1-FiPS4F1 (Spanish National Stem
Cell Bank) obtained from a healthy individual by the same
reprogramming strategy (Sendai virus, Cytotune, Thermo Fisher)
was used. Both cell lines were induced to differentiate toward
RPE following the previously published protocol (Lukovic et al.,
2015; Hongisto et al., 2017). Briefly, the iPSCs were cultured
in hESC medium (KO DMEM, KSR 20%, GlutaMAX 2 mM,
non-essential amino acids 0.1 mM, β-mercaptoethanol 0.23 mM,
basic FGF 10 ng/ml, and penicillin/streptomycin) on irradiated
(45 Gy) human feeder cells (ATCC CRL2429) at 37◦C under
5% CO2. When the colonies reached confluency, they were
lifted and cultured in suspension in the absence of bFGF until
the dark patches appeared. The dark patches were excised,
trypsinized, and plated on collagen type IV/LN-521 coated plastic
cell culture dishes where they acquired the RPE morphology
within 4–8 weeks. RPE-like cells were passed through a 70-µm
cell strainer in order to reach a homogeneous, highly pigmented
RPE-like monolayer with characteristic uniform polygonal cell
morphology. The differentiation experiments were performed in
triplicates for both genotypes (Patient-RPE and Control-RPE).
The samples were collected from each differentiation experiment
(n = 3) and RNA extraction was performed.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA), washed
twice in PBS, and placed in blocking solution (3% normal
goat or donkey serum and 0.5% Triton-X 100 in PBS) for 1 h
at room temperature. Cells were then incubated overnight at
4◦C with one of the following primary antibodies: anti-PRPF8
(1: 200, Santa Cruz sc55534, Abcam ab79237), rabbit anti-
CRALBP (1:250, Abcam), rabbit anti-ZO1 (1:50, Invitrogen),
and mouse anti-Na/K-ATPase (1:100, Santa Cruz). The following
day, cells were washed three to five times in PBS and incubated
with an appropriate secondary antibody (1:500, Invitrogen).
After secondary antibody incubation, nuclei were stained with
4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) (Life
Technologies, #D1306) and washed three times in PBS. The
coverslips were mounted using Vectashield Mounting Medium
(Vector Lab, Burlingame, CA, United States) and imaged on Leica
confocal microscope SP8.
POS Phagocytosis Assay
Bovine rod POS were obtained from InVision BioResources (WA,
United States) and labeled with FITC. Phagocytosis assay was
performed as described previously (Lukovic et al., 2015). Briefly,
iPSC-RPE cells were incubated with POS for 2 h/37◦C, washed
with PBS, and fixed by 4% PFA. After permeabilization by 0.1%
Triton-X, phalloidin staining was performed and the samples
were mounted with Vectashield mounting media. The samples
were visualized by Leica confocal microscope SP8 using HCX
PL APO lambda blue 63X/1.4 OIL objective. The quantification
of POS particles was performed by imaging random fields from
three different experiments in each condition. Five images were
taken from each experiment. The relative intensity of internal
POS labeling was quantified using Image J, and the pairwise
comparison was performed using Student’s t test. Results are
expressed as the mean ± SD. Values of p < 0.05 were considered
statistically significant.
Western Blot
Fibroblast cells were lysed in RIPA buffer (R0278 Sigma)
containing a protease inhibitor cocktail (Roche), and total protein
was quantified using a Bradford Reagent protein assay (B6916
Sigma-Aldrich). Protein lysates were denatured by 1X SDS
Sample Buffer. The resulting samples were incubated at 95◦C
for 5 min. Protein samples (100 µg) were then separated on
TGX Stain-FreeTM Gels (Bio-Rad) and electroblotted onto a
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PVDF membrane (Trans-Blot R© TurboTM Transfer Pack/Bio-
Rad). Membranes were incubated in blocking buffer (5% non-fat
dried milk diluted in TBS + 0.1% Tween) for 1 h at room
temperature, washed three times in TBS + 0.1% Tween for
5 min, and incubated with primary antibody (PRPF8 Abcam
ab79237) at 1:500 dilution in blocking buffer overnight at 4◦C.
Thereafter, blots were washed three times in TBS + 0.1%
Tween and incubated with secondary HRP-conjugated antibody
in blocking buffer for 45 min at RT. Blots were washed another
five times and protein bands were visualized using SuperSignal
West Pico PLUS (Thermo Scientific) on X-ray films. β-ACTIN
(monoclonal, 1:4,000,000, Sigma-Aldrich A3854) was used as a
loading control. HiMark Prestained Protein Standard (LC5699,
Thermo) was used as a molecular weight standard.
Transmission Electron Microscopy
RPE cells were fixed in 4% PFA and 2% glutaraldehyde in 0.1
M sodium phosphate buffer (pH 7.2–7.4) for 2 h, washed with
the same buffer, and then postfixed in 1% OsO4 in PB. After
gradual dehydration in ethanol series, the pieces were embedded
in EPON 812. Semithin and ultrathin sections were obtained in
an ultramicrotome (Leica Ultracut R, Leica Microsystem). After
staining with lead citrate and uranil acetate, ultrathin sections
were examined in a JEM-1400 Plus electron microscope (JEOL
GmbH, München, Germany).
RNA-Seq Library Preparation and
Sequencing
High-quality total RNA (RIN > 7) from three independent
experimental replicates of Patient-RPE, Control-RPE, Patient-
fibroblasts, and Control-fibroblasts was extracted by RNeasy
mini kit (Qiagen, Germany) and quantified by Agilent 2100
Bioanalyser. Total RNA (200 ng) was used to generate barcoded
RNA-Seq libraries using the NEBNext Ultra RNA Library
preparation kit (New England Biolabs). First, poly A + RNA was
purified using poly-T oligo-attached magnetic beads followed by
fragmentation and first and second cDNA strand synthesis. Next,
cDNA ends were repaired and adenylated. The NEBNext adaptor
was then ligated, followed by uracil excision from the adaptor
and PCR amplification. The size of the libraries was checked
using the Agilent 2100 Bioanalyzer and the concentration was
determined using the Qubit R© fluorometer (Life Technologies).
Libraries were sequenced on a HiSeq2500 (Illumina) to generate
60-base (sequencing batch 1) or 50-base (sequencing batch 2)
single-end reads, to a mean depth of 100M reads/sample for
one replicate for each condition (sequencing batch 1) and a
mean depth of 20M reads/sample for the other two replicates
(sequencing batch 2). FastQ files for each sample were obtained
using CASAVA v1.8 software (Illumina).
RNA-Seq Analysis
Read Mapping, Quantification and QC
Quality control assessments for raw RNA-Seq reads
were performed using fastqc (version 11.5)2. TruSeq
2http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
Illumina adapters (3′ adapters, sequence: AGATCGGAAG
AGCACACGTCTGAACTCAGTCA) were removed using
cutadapat (version 2.5, option –discard-trimmed activated,
detected 2–5% reads with adapters) (Anders et al., 2015).
Then, the STAR aligner (version 2.7.3a, median 89.3% reads
mapped) was used for mapping the reads to the human genome
(GRCh38.p7) using the ENSEMBL transcriptome (release 87)
(Yates et al., 2020). Gene-level counts were obtained using
HTSeq (Anders et al., 2015) (htseq-count, version 0.11.0, median
79.5% of reads assigned to genes). Mapping QC was performed
using Qualimap (version 2.1.2) and MultiQC (version 1.7)
(Ewels et al., 2016).
Gene-level counts were normalized using Trimmed Mean
of M Values (TMM) (Robinson and Oshlack, 2010). RNA-Seq
QC was performed using NOISeq (version 2.30.0) (Tarazona
et al., 2015), removing features with mean expression < 1 Count
per Million (CPM) across all samples. Batch effects between
sequencing batches were then corrected using the ARSyN
method (implemented in NOISeq) (Nueda et al., 2012). Principal
Component Analysis (PCA) was performed using the prcomp()
function included in the stats R package (version 3.6.3).
Differential Expression and Functional
Enrichment Analysis
Differential expression (DE) analysis was performed using
NOISeqBio (Tarazona et al., 2015). Four contrasts were
performed to obtain DE genes (p value <0.05—equivalent to
NOISeq probability > 0.95—and log2FC ≥ 1) between all
meaningful pairs of clinical conditions and cell types: (A) two
within-cell type contrasts to compare clinical conditions for the
same cell type, i.e., Control-Fibroblasts vs. Patient-Fibroblasts
and Control-RPE vs. Patient-RPE; and (B) two within-condition
contrasts to detect differences between cell types for the same
clinical condition, i.e., Control-Fibroblasts vs. Control-RPE and
Patient-Fibroblasts vs. Patient-RPE.
To better interpret the DE results, we used the information
in the control and fibroblast contrasts to filter the results
of the patient and RPE contrasts, respectively. In particular,
in the within-cell type contrasts, DE genes found in the
Control-Fibroblasts vs. Patient-Fibroblasts that were common
to the Control-RPE vs. Patient-RPE were removed from the
latter list (Supplementary Table 1). Since fibroblasts present
no disease phenotype, any differences in expression between
fibroblasts from both clinical conditions is expected to arise
from technical effects and non-phenotype-related biological
effects and is considered to be a source of interference for
correct interpretation. In case of the within-condition contrasts,
we considered only unique DE genes detected in the control
(Control-fibroblasts vs. Control-RPE) and patient (Patient-
fibroblasts vs. Patient-RPE) contrasts and removed common DE
genes from both. In this manner, we address differences in
expression related to encoding of the healthy RPE phenotype that
are lost in the disease (DE in control contrast, and not DE in
patient contrast) as well as expression changes that arise due to
the RP disease and were not present when comparing healthy
cells (DE in patient contrast, and not DE in control contrast).
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Functional Enrichment analysis of these sets of DE genes was
performed for Gene Ontology (GO) annotations [retrieved using
the biomaRt (Durinck et al., 2005) R package version 2.42.1,
GO database accessed December 2019 (Ashburner et al., 2000;
Carbon et al., 2019)] using Fisher’s Exact Test and Benjamini–
Hochberg’s multiple-testing correction method (significance
threshold: adj p value <0.05).
Alternative Splicing Event Analysis and
Functional Enrichment of Alternatively
Spliced Genes
Alternative splicing (AS) event analysis was performed for
the same four contrasts as in DE analysis using SUPPA2
(version 2.3) (Lareau and Brenner, 2015). The RefSeq human
transcriptome (RefSeq release 96) (O’Leary et al., 2016) was
used to define splicing events via the generateEvents function
in SUPPA2. We then mapped sequencing reads to the human
genome (GRCh38.p13) using STAR [ref STAR] (version 2.7.3a)
and the same RefSeq transcriptome and obtained isoform-level
expression estimates using RSEM (version 1.3.0) (Yates et al.,
2020). Transcripts per Million (TPM) values were then used to
obtain a Percentage Spliced In (PSI) value per splicing event using
the psiPerEvent function (SUPPA2). Next, differential splicing
analysis was performed using the diffSplice function (SUPPA2)
to obtain the PSI difference (dPSI) and p value for the splicing
change in the four contrasts of interest.
In order to obtain alternatively spliced genes for each contrast,
we performed several filtering steps. For the within-cell type
contrasts, events with a significant splicing change (p value
<0.05) in both the fibroblast (Control-Fibroblasts vs. Patient-
Fibroblasts) and RPE (Control-RPE vs. Patient-RPE) contrasts
were removed from the latter to preserve only splicing differences
related to the disease retinal phenotype (Supplementary Table 2).
In the case of the within-condition contrasts, we removed
common alternatively spliced events from the significant events
obtained in each of the two contrasts, i.e., Control-fibroblasts
vs. Control-RPE and Patient-fibroblast vs. Patient-RPE. Hence,
significant events unique to the control were considered to
be associated to splicing differences encoding the healthy
phenotype that are then lost in the patient, while unique
patient events were interpreted as arising as a result of the
disease and the PRPF8 mutation. In this, case, however, we also
considered common significant events changing the sign of dPSI
between contrasts.
Functional enrichment analysis of differentially spliced genes
was performed as described in the previous section. As our list of
splicing-related genes, we performed a text-mining search of GO
terms containing the words “mRNA”, “pre-mRNA”, “splicing”,
“spliceosome”, “spliceosomal”, and “rRNA” (total GOs: 106)
and selected all genes annotated for at least one of these
GOs (total genes: 987). A complete list of all considered GO
terms is provided in Supplementary File 9. We note that
some false-positive AS-related GOs may arise from this type
of search; however, it is designed to be as comprehensive
as possible in order to provide interesting candidates for the
RP disease. Annotations are subsequently manually checked,
and only truly AS-related genes are discussed and considered
in the manuscript.
RESULTS
Patient-Specific iPSC-RPE Cells Reveal
Normal Cellular Phenotype
We previously identified an adRP patient with the
heterozygous mutation in PRPF8 (NM_006445:c.6974-
6994del, p.Val2325_Glu2331del) (Martinez-Gimeno et al.,
2003) (Supplementary Figure 1). This mutation affects the
C-terminal region of the PRPF8 within a region required for
interaction with EFTUD2 and SNRNP200 (Pena et al., 2007).
This 21-base pair deletion results in Val2325 to Glu2331 amino
acid deletion at the C-terminal segment (Supplementary
Figure 1) leading to the loss of a polar contact between the N
atom of Lys592 in SNRNP200 and the O atom from Leu2333 in
PRPF8 (Supplementary Figure 2).
The iPSCs were derived from the patient and differentiated
toward RPE cells according to the previously described procedure
(Figure 1A; Hongisto et al., 2017). As a control, a healthy subject’s
iPSCs were differentiated toward RPE. The obtained RPE cells
exhibited typical native RPE traits including the formation of
a cellular monolayer with a polygonal shape and pigmented
cells and showed expression of RPE markers such as cellular
retinaldehyde-binding protein (CRALBP), sodium/potassium-
dependent ATPase (Na+/K+ ATPase) with predominantly apical
distribution, and zonula-occludens-1 (ZO-1), a tight-junction
marker, with typical apico-lateral distribution (Figure 1B).
PRPF8 exhibited typical nuclear punctate distribution in control
and patient’s RPE, with the antibody that recognizes the N-
and C-terminal end without any significant difference between
two genotypes. The defective protein is 2,328 amino acids long
compared to the wild-type, 2,335-amino-acid-long protein. This
difference in size could not be detected by Western blot using
the antibody raised against the N-terminus (Figure 1D) or the
one recognizing the C-terminal amino acids (2,036–2,335) (data
not shown). The identity of the iPSC-derived RPE cells was
validated using RNA-Seq data, i.e., by DE analysis of several
RPE trait markers (BEST1, MERTK, MITF, RLBP1, and RPE65)
(Strunnikova et al., 2010) between fibroblasts and RPE cells in
each condition (control and patient). Indeed, all these markers
are upregulated in the RPE cells in comparison to fibroblasts,
with comparable intensity in both control and disease cells
(Supplementary Figure 3).
To further confirm the identity of RPE cells, ultrastructural
analyses were performed and characteristic polarized RPE
morphology was detected in Patient-RPE (Figure 1E) and
Control-RPE (data not shown). The polarized organization of
cuboidal cells typical of RPE was observed with basally positioned
nuclei and apically distributed microvilli (Figure 1E, left panel).
Melanosomes represented with black round and oval shapes
were present in the apical portion of the cells while ellipsoidal
mitochondria were seen below the nuclei, largely displaced
toward the basal-lateral part of the cells, the natural position for
these organelles in vivo. Intercellular junctional complexes are
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FIGURE 1 | Generation of iPSC-RPE cells from patient and control. (A) Schematic of iPSC differentiation toward RPE. (B) Characterization of iPSC-RPE. Bright-field
images of iPSC-RPE monolayers. Immunocytochemistry to PRPF8 and characteristic RPE markers CRALBP, Na+/K+-ATPase (Na/K), and ZO-1. Vertical simulation
sections for Na+/K+ ATPase show mainly apical distribution and ZO-1 showing typical apical lateral junction distribution. (C) POS phagocytosis assay: FITC-labeled
POS (green); F-actin is stained by phalloidin (red) to visualize cell morphology and internalization of POS and quantitative analyses of ingested POS. (D) Western blot
analysis of PRPF8. (E) Transmission electron microscopy of patient iPSC-RPE. Left panel: cuboid polarized RPE cell organized in monolayer with basally located
nucleus (n) and apically distributed microvilli (mv). Right panel: RPE cells show melanin granules (red arrowheads) apically from the nucleus, intercellular junctional
complexes that include the tight junctions, adherens junctions (arrows), and membrane interdigitations (arrowheads), and basally positioned nucleus (n).
(F) Contrasts analyzed by RNA-Seq. Created with BioRender (https://biorender.com/). Data are expressed as means ± SD, n = 3 assays from two differentiation
experiments; Student’s t test, n.s., non-significant. Scale bar 25 µm where not indicated.
visible in appropriately aligned sections of RPE (Figure 1E, right
panel). Again, the patient’s RPE showed the main hallmarks of
native RPE without any morphological differences compared to
healthy individual control. Furthermore, we assessed the ability
of iPSC-RPE to phagocytose POS, mimicking a daily rhythmic
binding and internalization of POS tips by RPE cells essential for
vision. The ability of patient and control iPSC-RPE was compared
by quantifying the FITC-labeled POS fluorescence inside the
cells. The results indicate that the disease and control iPSC-RPE
ingested the photoreceptor membranes similarly (Figure 1C).
Functional Analysis of Gene Expression
Differences Between Patient and Control
Cells
In order to assess the transcriptional changes associated with
disease, four pairwise comparisons between samples were
performed in order to obtain DE genes between each relevant
pair of conditions (Figure 1F and Supplementary Files 1–4).
Supplementary Table 1 summarizes the number of DE genes
between each pair of conditions. Within-condition contrasts
(RPE vs. fibroblasts for either patient or control samples) were
performed to reveal differences related to the cell type identity,
while the within-cell type contrasts (i.e., comparing patient vs.
control for the same cell type) had the potential to unravel
differences associated with the disease and the PRPF8 mutation.
PCA of the different sample types (Supplementary Figure 4)
indicated that cell-type differences (RPE vs. fibroblasts) explained
the highest variance across samples (∼50%, PC1), followed by
expression changes between the clinical conditions (∼13%, PC2).
Nevertheless, the expression profile between healthy and disease
RPE cells presented more differences than that of fibroblasts, as
expected given that the PRPF8 mutation presents a phenotype
only in the retina.
For the within-cell type contrasts (Supplementary
Files 1, 2), DE analysis of Patient-RPE vs. Control-RPE
was performed [False Discovery Rate (FDR)-adjusted p
value <0.05], subsequently filtering genes that were also DE
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FIGURE 2 | Functional enrichment results for differential gene expression. Significantly enriched (FDR < 0.05) Gene Ontology terms for (A) Patient-RPE vs.
Control-RPE contrast, filtering genes that are DE between patient and control fibroblasts. (B) Patient-RPE vs. Patient-fibroblasts, filtering genes that are DE in the
control contrast, and (C) Control-RPE vs. Control-fibroblasts, filtering genes that are DE in the disease contrast. Dot size indicates significance of the Fisher’s Exact
Test [–log(adj p value)], x-axis position indicates the number of DE genes that are annotated for each significant GO term, and dot color indicates the GO aspect
under which the term is annotated.
in Patient-fibroblasts vs. Control-fibroblasts (see Materials
and Methods). We considered this set of DE genes (4,644,
Supplementary Table 1) to be RPE-specific and therefore
to encode a relevant part of the transcriptional signature
of the disease. Functional enrichment analysis of this set of
genes identified significantly enriched (Fisher’s Exact test,
FDR < 0.05) GO terms, namely, G-protein coupled receptor
activity [GO:0004930, 67 genes, 45 (67%) upregulated in patient]
and several extracellular matrix-related terms [GO:0005578,
GO:0005201, GO:0030198; 92 genes in total, 70 (76%)
upregulated in patient] (Figure 2A). This suggests a coordinated
increase in expression for these genes in the disease condition.
However, some of these genes are depleted in the patient
condition and could also contribute to create an imbalance of
these functions in the RP disease. Interestingly, none of the 67
genes annotated as G-protein-coupled receptor activity genes
were differentially spliced in any of the comparisons performed
(see the next section). Therefore, expression dysregulation
without splicing alterations could be considered a secondary
effect of the PRPF8 mutation. Among 92 genes annotated under
an extracellular-matrix-related term, some show a splicing
change in the within-cell-type contrasts, namely, COL5A1,
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FN1, LAMA2, VEGFA, and HAPLN3. All except HAPLN3
show differential splicing for at least one event in all contrasts,
suggesting a possible direct impact of the mutated splicing factor.
Regarding the two within-condition contrasts (Control-RPE
vs. Control-fibroblasts and Patient-RPE vs. Patient-fibroblasts,
Supplementary Files 3, 4), we filtered common DE genes to
obtain transcriptional signatures of RPE cell-type identity, i.e.,
healthy and disease RPE phenotypes. We observed 4,903 unique
DE genes (p < 0.05) for the control comparison (Supplementary
Table 1), which represent differences in expression between RPE
and fibroblasts required for encoding healthy cell-type identity
and presumably lost due to the disease mutation. For the disease
condition, 1,838 unique DE genes were identified (p < 0.05,
Supplementary Table 1), probably related to the development
of the disease in RPE cells. The majority of common DE genes
(7,491) present a similar change in expression between both cell
types, supporting the robustness of the transcriptional differences
between RPE and fibroblasts (Supplementary Figure 4).
Functional enrichment analysis of DE genes unique to the
patient contrast (Patient-RPE vs. Patient-fibroblasts) identified
significant enrichment (Fisher’s Exact test, FDR < 0.05) of a
broad set of biological functions related to cell division and
the cytoskeletal elements participating in mitosis, including
spindle (GO:0005819), chromosome segregation (GO:0007059),
and kinetochore (GO:0000776) (Figure 2B). The functional
enrichment analysis for DE genes unique to the control contrast
(Control-RPE vs. Control-fibroblasts) included a much wider
range of significantly overrepresented (Fisher’s Exact Test,
FDR < 0.05) biological processes, including mitosis-related
GOs, but also terms associated to splicing (spliceosomal complex,
GO:0005681; mRNA splicing via spliceosome, GO:0000398;
mRNA 3′-end processing, GO:0031124; nonsense-mediated decay,
GO:0000184) and ribosome structure and translation (ribosomal
subunits, GO:0022625 and GO:0022627; rRNA processing,
GO:0006364; translational initiation, GO:0006413 SRP-
dependent cotranslational targeting of membrane, GO:0006614)
(Figure 2C). Ribosome/translation-related terms included 76
genes, of which 69 (91%) were upregulated in Control-RPE.
This coordinated upregulation does not appear in the case of the
patient contrast, suggesting depletion of ribosomal functionality
in Patient-RPE when compared with fibroblasts of the same
clinical condition. Meanwhile, AS-related terms included a
total of 45 genes, 26 (58%) of which were downregulated in
Control-RPE, showing a relative balance of up-/downregulation
of AS genes. In the patient contrast, no coordinated DE or
significant overrepresentation was observed and pinpoints to
the dysregulatory effect of the PRPF8 mutation on splicing
machinery components, which have been shown to undergo
widespread regulation by post-transcriptional mechanisms
(Lareau et al., 2007; Ni et al., 2007; Han et al., 2010; Anko et al.,
2012; Lareau and Brenner, 2015).
AS Signature of Healthy and Disease
RPE Cells
In order to shed light on the mutant PRPF8 pathomechanism,
we analyzed splicing patterns in the different cell types and
clinical conditions and we evaluated the difference in Percentage
Spliced In (dPSI, see section “Materials and Methods”) for each
of the four contrasts (Figure 1D and Supplementary Files 5–8),
considering the following splicing event categories: alternative 3′
and 5′ site (A3/A5), alternative first (AF) and alternative last (AL)
exon, mutually exclusive (MX) exons, retained intron (RI), and
skipped exon (SE) (Trincado et al., 2018).
For the within-cell-type comparisons (Supplementary
Files 5, 6), we observed a higher number of splicing events
with significant differences (p value <0.05) when comparing
RPE cells from different clinical conditions than in the case
of fibroblasts (Supplementary Figure 5), which we attributed
to the high complexity of splicing in RPE (Strunnikova et al.,
2010; Farkas et al., 2013) and the fact that fibroblasts show
no disease phenotype as a result of the PRPF8 mutation.
After removing common significant events from the RPE
contrast (Supplementary Table 2), we used dPSI values to
check the direction in the splicing change, i.e., the clinical
condition in which event inclusion is promoted for RPE
cells (Figure 3). A strong tendency toward inclusion of RI
events can be observed in Control-RPE in comparison with
Patient-RPE, as well as promoted inclusion of A3 and A5 sites,
while there were no global direction change patterns in AF,
AL, or SE events.
We next performed a functional enrichment analysis of genes
with at least one significant AS event, removing events common
between the fibroblast and RPE contrasts as previously described
for the DE analysis (see section “Materials and Methods”).
Functional analysis of events unique to the RPE contrast
showed no significantly overrepresented terms (FDR < 0.05).
Hence, we ranked GO terms by their frequency of annotation
in alternatively spliced genes to gain functional insight into
the splicing patterns of the disease. The most frequently
annotated GO terms were RNA polymerase II DNA binding
(GO:0000977), including several alternatively spliced zinc finger
genes (ZNF154, ZNF211, ZNF419, and ZNF691), as well as
ribosome (GO:0005840) and structural constituent of ribosome
(GO:0003735), which included some genes also annotated for
mitochondrial translation, i.e., Mitochondrial Ribosome Protein
genes from the Large subunit (MRPL genes). In addition, several
splicing-related terms were among the most frequently annotated
(Figure 4), namely, spliceosomal complex (GO:0005681) and
catalytic step 2 spliceosome (GO:0071013). Genes under these
annotations included PRPF4, PRPF8, and PRPF31, known to
be involved in RP (Sullivan et al., 2006; Chen et al., 2014),
as well as SRSF1, HRNPA2B1, and SRRM2 (Figure 5). This
suggests a high level of functional dependence between different
spliceosome components that have been shown to cause RP
and seems to further indicate that PRPF8 malfunction may
propagate to other spliceosome components to generate the
disease phenotype. In fact, SRRM2 and SRSF1 are also DE in the
RPE contrast (downregulated in patient). Therefore, the PRPF8
mutation could have a dual role in altering both the expression
and the splicing of other spliceosomal genes and, potentially, their
function. Ultimately, we hypothesize that the RP disease would
be caused by the cumulative effect of these alterations in the
splicing machinery.
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FIGURE 3 | Summary of alternatively spliced events (p value <0.05) in the RPE contrast. Only events unique to the Control-RPE vs. Patient-RPE contrast are
shown. The proportion of events for which inclusion is favored in each clinical condition is indicated by the bar area. The number of events for each category is
shown in the label above the bar. Event types: A3, Alternative 3′ site; A5, Alternative 5′ site; AF, Alternative First exon; AL, Alternative Last exon; MX, Mutually
Exclusive Exons; RI, Retained Intron; SE, Skipped Exon.
FIGURE 4 | Functional enrichment results for differentially spliced genes in the RPE contrast (Control-RPE vs. Patient-RPE, only unique events). The top-10 most
frequently annotated GO terms are shown in the y-axis. The number of genes belonging to each GO term is indicated by bar height (x-axis).
In order to better understand the mechanism by which the
PRPF8 mutation caused mis-splicing in splicing-related and non-
splicing related genes, we analyzed the relationship between gene
expression and splicing for each type of event (Supplementary
Figures 6–9). Regarding RI events, we observed increased
intron retention in Control-RPE that seemed to be decoupled
from transcriptional regulation (Supplementary Figure 6), since
intron retention does not appear to be related to a pattern
of gene downregulation in the control condition. Nevertheless,
SRSF1 and PRPF4B, the latter involved in AS, contradicted this
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FIGURE 5 | Splicing-related genes with at least one differentially spliced event (p value <0.05) in the Control-RPE vs. Patient-RPE contrast (only genes unique to the
RPE contrast are considered). Each event is colored by type (A3, alternative 3′ site; A5, alternative 5′ site; RI, retained intron; SE, skipped exon). dPSI is shown in the
y-axis (dPSI < 0: event inclusion favored in control, bottom panel; dPSI > 0: event inclusion favored in patient, upper panel). log2(Fold Change) is shown in the
x-axis (FC < 0: gene downregulated in patient, left panel; FC > 0: gene upregulated in patient, right panel).
pattern and showed highly included IR events in Patient-RPE,
together with a decrease in expression in this clinical condition.
This deviation from the general pattern for SRSF1 and PRPF4B
agrees with previous reports of increased intron retention in RP
(Martinez-Contreras et al., 2007) as well as with its established
role in decreasing expression levels of transcripts (Braunschweig
et al., 2014) and may suggest a direct role for PRPF8 in the
splicing of these two genes, which generates an imbalance in
coding vs. non-coding isoforms when the mutation is present.
In the case of SE events, we observed a similar number
of patient and control-favored inclusion of alternative exons
(Supplementary Figure 7). However, there seems to be a global
tendency toward downregulation in patient for this group of
genes. Importantly, this category of events includes alternatively
spliced HNRNP genes (HRNPA2B1, HNRNPDL, HNRNPAB),
which are known to participate in splicing control (Martinez-
Contreras et al., 2007) as well as the RNA-binding protein
MTHFSD, whose deregulation has been previously linked to
disease (MacNair et al., 2016).
Regarding A5 and A3 sites, we observed very different
behavior as a response to the mutation in PRPF8. While few
A5 sites showed a significant splicing change (Supplementary
Figure 8), with inclusion of the alternative portion of the
exon being favored neither in patient nor in control, our
analyses revealed a strong tendency toward A3 site inclusion
in the Control-RPE (Supplementary Figure 9). Patient-RPE
therefore showed more frequent usage of the A3 sites within
these exons, while healthy cells (Control-RPE) tend to use the
site that generates a longer exon. These results suggest an
interaction between PRPF8 and the 3′ splice site. In addition,
these splicing changes do not seem to be related to a DE pattern
when comparing patient and control RPE cells (Supplementary
Figure 9). Therefore, this PRPF8-mediated global A3 event
inclusion, potentially caused by the mutation, would solely be
associated to post-transcriptional regulation, in contrast to SE
and IR results. AS-related genes showing this pattern included
previously discussed SRSF5, PRPF31, HRNPA2B1, and SRRM2, as
well as splicing factor SFPQ and RNA methyl-transferase NSUN5
(Supplementary Figure 9).
AS Signature Encoding Healthy and
Disease Cell-Type Identities of RPE Cells
Aiming to understand the contribution of AS to RPE cell
identity, we analyzed within-condition changes in AS events
(Supplementary Files 7, 8). We presumed significant AS events
and AS genes unique to the control contrast (Control-fibroblasts
vs. Control-RPE) to be key determinants of healthy RPE cells that
are no longer present in the patient contrast. Meanwhile, unique
significant AS events and genes in the patient contrast (Patient-
fibroblasts vs. Patient-RPE) constitute splicing alterations that
arise due to the disease. This analysis revealed an overall
decrease in the number of significant events (p value <0.05) in
the patient contrast (Supplementary Figure 10), which could
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FIGURE 6 | Summary of unique alternatively spliced events (p value <0.05) detected in the control (A, Control-fibroblasts vs. Control-RPE) and patient (B,
Patient-fibroblasts vs. Patient-RPE) contrasts. The proportion of events for which inclusion is favored in each clinical condition is indicated by bar area. The number
of events for each category is shown in the label above the bar. Event types: A3, Alternative 3′ site; A5, Alternative 5′ site; AF, Alternative First exon; AL, Alternative
Last exon; MX, Mutually Exclusive Exons; RI, Retained Intron; SE, Skipped Exon.
be attributed to a depletion in spliceosomal function caused
by PRPF8 mutation.
We next used the dPSI values to look at event
inclusion/exclusion patterns between cell types in each clinical
condition (Figure 6). Regarding AF and AL events, there were
no trends in either clinical condition, or high variation in the
number of events with a significant splicing change between
control (Figure 6A) and patient (Figure 6B). Interestingly,
events in the rest of the categories showed preferential inclusion
in one cell type in at least one of the clinical conditions or
a drastic change in the number of significant AS events. AF
and AL events are generated due to alternative start/end sites
for transcription and therefore correspond to transcriptional
regulation mechanisms, which further supports the hypothesis
that the PRPF8 mutation has its effect via the alteration of post-
transcriptional regulation, i.e., splicing. In the case of RI, while
intron inclusion was favored in fibroblasts for most RI events in
the patient contrast (which matches the decrease in RI detected
for Patient-RPE in the within-cell type contrasts), the control
contrast revealed a higher degree of intron retention in RPE. Of
note, the number of significant RI events was much higher in the
control contrast (108) in comparison to patient (20), suggesting
the existence of an intron retention program that could be
important for the determination of the healthy RPE phenotype.
A3 and A5 events also tended to be less included in RPE in the
patient contrast in comparison to the control, which revealed
coordinated usage of exon alternative sites in Patient-RPE, as
could be observed for A3 sites in the RPE contrast. Ultimately,
this suggests a change in the way that PRPF8 interacts with
both the 3′ and 5′ splice sites in the RP disease. Functional
enrichment analysis of unique AS genes showed no significantly
overrepresented GO terms (FDR < 0.05) in either contrast. We
therefore looked at the frequencies of GO term annotations
for these genes (Figure 7). Interestingly, genes whose splicing
status encodes the healthy RPE phenotype (control contrast)
are frequently annotated for spliceosomal complex (GO:0005681,
9 genes) and rRNA processing (GO:0006364, 9 genes), two
functional terms that appear linked to the PRPF8 mutation and
RP throughout this study. These findings are in line with our
hypothesis regarding the existence of a healthy splicing signature,
involving spliceosome and ribosomal genes, that is required to
maintain correct retinal function and is disrupted via splicing
defects initiated with defective PRPF8. Another cell function
that was shown to be enriched in genes DE in the control
contrast (Figure 2), regulation of cell proliferation (GO:0042127,
eight genes), was the only common GO term among the most
frequent annotations.
Finally, we studied the events that change in each within-
condition contrast for the genes annotated under these three
GO terms (Supplementary Figures 11–15). Regarding rRNA
processing genes (Supplementary Figure 11), we observed
variable trends regarding the cell type in which inclusion of
the AS events is favored. While PLXNB3, CFAP410, and RHOJ
presented SE events that showed inclusion in fibroblasts, a
similar event in MKLN1 was included in RPE. Regarding event
categories, although several genes showed differentially spliced
AF exons, we did not observe a pattern among significant
event types for rRNA processing genes. However, FN1 and
RASA1 present A3 and A5 sites, respectively, showing inclusion
in RPE, matching the previously described trend (Figure 6).
For spliceosome genes (Supplementary Figure 12), however,
we noticed that most significant events were IR, A3 and
A5 sites, while very few events within these three categories
were observed in rRNA processing genes (Supplementary
Figure 11). The abundance of A3 and A5 events changing among
splicing-related genes could further support our hypothesis that
WT PRPF8 is involved in spliceosomal binding to the splice
sites. Indeed, all A3 and A5 sites showed inclusion in RPE
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FIGURE 7 | Functional enrichment results for differentially spliced genes (p value <0.05) in the within-condition contrasts. (A) Control-fibroblasts vs. Control-RPE.
(B) Patient-fibroblasts vs. Patient-RPE. Only events unique to each contrast are considered. The top-10 most frequently annotated GO terms are shown in the
y-axis. The number of genes belonging to each GO term is indicated by bar height (x-axis).
(Supplementary Figure 12) and therefore selection of the splice
sites that generated longer exons. This splicing change is lost
in the patient contrast, suggesting a lack of control over this
process in the disease for these set of spliceosomal genes,
which include helicase DHX37, ribosomal components RPL15
and RPL31, and several ribosome maturation factors and rRNA
processing proteins. The exact role of splice site selection in the
RP disease, however, requires further validation and is beyond the
scope of this study.
Genes annotated for regulation of cell proliferation were the
only functional group that was frequently annotated among AS
genes in both clinical conditions, although the sets of genes
in each contrast are different, with the exception of NF2. In
the case of this gene group, most splicing changes occurred
in SE and AF events, except for an A5 event detected in the
control contrast (STAT6) and an A3 event in patient (ITSN1). We
consider these, together with genes presenting SE events (control:
CNN2, IL4R, PKD2, and PIAS1; patient: MYH10, PALLD, and
WASF2), to be genes subject to strong post-transcriptional
regulation and therefore candidates for future evaluation of
the impact of these splicing changes on RPE function. Finally,
among the 371 common events (significant in both contrasts),
we found 14 events that presented different dPSI sign in the
patient and control comparisons (Supplementary Figure 15),
i.e., alternatively spliced events with different direction of
change depending on the clinical phenotype. In addition to
transcriptionally controlled AF exons, common events consisted
mainly of SE that presented preferential inclusion in RPE in the
control contrast (MRPS31, MTX1, SHLD2P3, and HNRNPDL),
while the exon becomes excluded in RPE in the patient contrast.
This set of genes included HNRNPDL, associated with pre-mRNA
processing. A similar trend is observed for A3 events in the
CYB5D1 and TPM2 genes, as well as for an RI event in the
SNORD locus (C/D box Small Nucleolar RNAs).
In summary, after performing within-condition contrasts, we
have observed a pattern of event inclusion in the control contrast
that is lost in patient, when not completely reversed, as is the
case of common genes. This mainly affects SE, A3, and A5
events for genes involved in splicing, rRNA processing, and
proliferation. The role that the skipped exons or exon fragments
play in the gene’s functionality is to be defined; however, our
analyses suggest that the PRPF8 mutation creates this event
exclusion pattern. We believe that these changes could alter the
splicing signature required for healthy RPE identity and that they
may be a consequence of AS dysregulation in the RP disease.
Ultimately, this list of alternatively spliced events and genes
should constitute a valuable resource for further validation in
order to find candidates that can explain the PRPF8-mediated
RP pathomechanism.
DISCUSSION
Despite huge progress in the identification of genetic causes of
the disease, the pathomechanism behind RP is largely unknown.
While animal models have proven useful in many cases, albeit in
the case of splicing factor-induced RP, they remain insufficient
as the disease phenotype is poorly manifested. Moreover, the
wide mutational landscape of splicing factor-caused RP is time-
and cost-consuming to capture in animal models. In addition,
studying disease-causing variants in genetic backgrounds that are
demonstrably permissive of the disease is highly desirable in the
case of splicing factor-induced RP due to high clinical diversity.
We set out to explore the transcriptional landscape of patient
non-affected and affected cells in order to elucidate the unique
role of PRPF8 in its target cells, namely, RPE cells vs. non-retinal
tissue. The use of iPSCs that can be differentiated toward any
human tissue leverages the lack of access to native retinal tissue.
After differentiation to RPE, patient and control cells
were indistinguishable upon assessment of morphological,
immunoreactive markers. We did not observe basal
deposits or infoldings as described in the mouse model
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(Graziotto et al., 2011). PRPF8 immunofluorescence was
equivalent in both genotypes, likely as a result of mutant
protein escape from nonsense-mediated decay due to the
short C-terminal amino acid sequence loss. Additionally, after
assessing POS phagocytosis capacity, we found that patient
and control cells behave indistinctly. The difference with the
Prpf8H2309P/H2309P mice, which showed reduced phagocytosis,
possibly lies in the homozygous state of the causative mutation
in the rodent model. The lack of morphological or protein
marker expression differences between control and RP genotypes
probably reflects the late-onset disease phenotype that emerges
as a result of additional cumulative molecular events. It has
been previously described that modeling late-onset diseases
requires additional cellular insults, since reprogramming leads
to erasure of age markers in the original fibroblasts (Horvath,
2013; Miller et al., 2013). Similar results were reported by Foltz
et al. with PRPF8 (c.6901C > T, p.P2301S) mutant, who describe
iPSC-RPE with similar apicobasal polarity and phagocytosis
rate between the patient and gene-corrected isogenic line (Foltz
et al., 2018). The rationale behind using the conventional
differentiation paradigm toward disease-specific cell type in this
work is that mutations in ubiquitously present splicing factors
involved in a fundamental cellular process such as splicing is
expected to capture early cell-type-specific events prior to overt
morphological or functional degeneration.
We then examined mRNA expression and splicing patterns
in patient and control fibroblasts and iPSC-derived RPE cells
in order to decipher the tissue-specific pathomechanism of the
disease. Differential expression analyses between control and
patient RPE cell types identified G-protein coupled receptor
(GPCR) activity genes and extracellular matrix-related genes,
some of the latter also showing changes in AS. GPCRs, the
largest family of membrane proteins, act through ligand binding
and are responsible for a wide variety of physiological roles.
Extracellular matrix proteins are known to play a crucial role in
supporting RPE cells in vivo and in vitro (Sorkio et al., 2014).
RPE synthesizes components of extracellular matrix proteins of
Bruch’s membrane and interphotoreceptor matrix, both of which
are essential for RPE integrity and function. We hypothesize that
these genes could be directly involved in the disease mechanism
and constitute good candidates for further validation.
Within-condition differential expression analysis (fibroblasts
vs. RPE cells in healthy and disease condition) identified a set
of common DE genes associated with mitosis-related processes
and components. Importantly, control contrast-unique DE genes
showed significant enrichment of splicing and ribosome structure
and translation terms, while this signature was completely
lost in the patient contrast. This suggests that splicing and
ribosome-related processes could be important for cellular
identity specification and that their expression dynamics is
disrupted in PRPF8-caused RP. In this study, we propose
two hypothesis that could explain this mechanism. First, the
alterations in the expression of splicing-associated elements could
propagate to ribosomal components and translation regulators
that may require intervention of the spliceosome for their normal
expression. Alternatively, RPE cells may display translational
control mechanisms for sustaining RPE properties.
Out of 90% AS genes in humans showing AS, it is estimated
that 30% have tissue-specific isoforms (Xu et al., 2002). We set
out to identify RPE-specific AS patterns and assess whether these
tissue-specific splicing events were affected by the disease. To
globally profile AS, we analyzed five modes of splicing events,
all of which allow for a single gene to encode multiple protein
variants that can have different functional properties. Among the
within-cell-type contrasts, a higher number of significant splicing
changes were detected when analyzing AS events in RPE cells in
comparison to fibroblasts, consistent with the higher functional
complexity of RPE cells and the primary effect of the PRPF8
mutation on these cells. Retained introns, as well as alternative 3′
and 5′ sites, showed favored inclusion in Control-RPE compared
to Patient-RPE. Intron retention is classically considered as
a result of mis-splicing and regarded as a mechanism of
suppression of inappropriate transcripts presumably destined for
nonsense-mediated decay (Braunschweig et al., 2014). However,
emerging studies have demonstrated that introns are actively
retained in mature mRNA and may have specific roles in normal
physiology (Wong et al., 2016; Adusumalli et al., 2019). Some
of the most significantly differentially included intron retention
events belonged to genes annotated for splicing and ribosome-
related GO terms. These included splicing factors such as PRPF4,
PRPF8, and PRPF31, all of which are known to cause RP. Of note,
SRSF1 and PRPF4B were highly included in patient-RPE and also
downregulated in this condition.
For alternative first and last exons, which are equivalent to
Alternative Transcription Start and End Sites, inclusion was
not globally favored in any of the conditions. This is not
surprising, given that transcription start and end site choice
is driven by the transcriptional machinery, instead of by the
spliceosome, which operates after transcription is initiated, either
post-transcriptionally or simultaneously to transcription (Herzel
et al., 2017). The lack of global direction changes could indicate
that the disease phenotype is caused by the PRPF8 mutation
and that it directly involves splicing rather than transcriptional
alterations. Ultimately, usage of AL or AF sites could be stochastic
or a functional consequence of splicing alterations in certain
proteins, but hardly the root of the disease.
In sum, we identified 27 splicing-related genes, including
PRPF8, with at least one differentially spliced event between
Control-RPE and Patient-RPE. This result opens interesting
possibilities regarding the role of PRPF8 as a splicing factor,
regarding both autoregulation of AS of its own pre-mRNA and
that of 26 additional splicing factors. In the context of the RP
disease, PRPF8 may act as a master AS regulator in RPE cells,
targeting a broad set of splicing-involved genes, leading to the
propagation of defective PRPF8 function to the rest of the splicing
machinery via splicing dysregulation. Similar results have already
been described in literature, where the core splicing proteins
were found to regulate RNA processing and RNA-binding factors
(Saltzman et al., 2011). We hypothesize that these are suitable
candidate genes and events to be further validated as RP disease
markers and are key to explain how PRPF8-initiated splicing
defects propagate to the entire splicing machinery.
Within-condition contrasts showed a higher number of
significant AS changes in control over disease cells, similar to
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the DE results, indicating a depletion of spliceosomal function
by PRPF8 mutation. For instance, there were 108 significantly
changing intron retention events in the control vs. 20 in the
disease contrast. In addition, functional enrichment results for
control contrast AS genes identified splicing and ribosome-
related functions within the top 10 most frequently annotated GO
terms. These within-condition AS results corroborate splicing
machinery disruption hypothesis as a potential mechanism
for PRPF8-induced RP. Meanwhile, the only common term
between control and disease cell types was regulation of cell
proliferation, although different genes were identified as AS
in each condition’s contrast. This finding is in line with
previous reports where PRPF8 was found to affect mitotic
cell cycle and RNA splicing GO terms after its depletion
by siRNA (Wickramasinghe et al., 2015). After removing
genes common to both contrasts, we identified sets of AS-
related genes in the control but not in the patient contrast,
which were involved in spliceosome machinery, ribosomal
structure, and translation, according to GO annotations. The
loss of these splicing patterns when comparing disease cells
is an additional evidence of the propagation of alterations
in the expression and splicing of spliceosomal components
to ribosomal proteins and translation regulators, which may
require intervention of the spliceosome for their normal
expression. Alternatively, and in line with the second proposed
hypothesis, RPE cells may display unique human translational
control mechanisms for sustaining RPE properties, which are
disrupted due to the pathomechanism of mutant PRPF8.
However, either of these hypotheses would require further
experimental validation.
AS has been previously described to be affected in the PRPF8-
depleted condition by siRNA in established cell lines (Tanackovic
et al., 2011). Although these conditions do not capture the
physiological cell environment and co-expression of the wild-
type protein, the data support the role of splicing defects in
PRPF8 pathomechanism. Similarly, in a comprehensive PRPF31
study using iPSC-derived RPE cells, differential exon usage was
found to affect splicing process itself (Buskin et al., 2018).
Moreover, AS GO term analysis of mouse Prpf 31+/− retina and
RPE were enriched for genes involved in mRNA processing.
The iPSC-RPE from the PRPF31-affected patients exhibited a
range of cellular defects, including loss of apico-basal polarity,
altered pigment epithelium-derived factor (PEDF), and basal
vascular endothelial growth factor (VEGF) secretion, barrier
function, phagocytosis, and primary cilia deficiencies. These data
are supportive of disrupted AS as a trigger of splicing deficiencies
underlying specific biological processes. The observed splicing
differences in our iPSC-RPE bearing a mutant PRPF8 copy points
to a common primary pathogenic event. The fact that we did
not observe morphological and functional disruptions in studied
cells can be attributed to a unique PRPF8 mechanism. Another
possibility is that our iPSC-RPE were insufficiently matured,
which delayed the concomitant cellular events. In that regard,
efforts for quantitative quality control to assess maturity instead
of image-based analyses are emerging (Plaza Reyes et al., 2020).
Parallel studies with both genetic backgrounds are warranted in
order to delineate the specific roles of each PRPF gene.
Of note, our study is limited by the small sample sizes in our
experimental design. Therefore, further studies involving a larger
number of patients would be required to confirm the findings
described herein. It is also imperative to determine if different
mutations of PRPF8 have a similar impact on the transcriptional
profile. As an additional shortcoming, we are aware that the
poly(A)-selected RNA profiling described here precludes the
involvement of other biologically relevant RNA species, such as
microRNAs or long non-coding RNAs, which may also play a role
in PRPF8-induced RP (Zhang et al., 2014).
The development of therapies for autosomal dominant retinal
diseases with gain-of-function mutations involve strategies to
inhibit expression of mutant protein and reduce the ratio
of malfunctioned to wild-type protein. Along these lines,
DNA oligonucleotides complementary to the pathogenic mRNA
(Murray et al., 2015) or gene editing by CRISPR/Cas system
targeting mutant allele (Bakondi et al., 2016) were described.
These patients would also benefit from gene-independent
replacement therapies such as heterologous stem cell replacement
or combined genetic and stem cell approach using autologous
cells. Importantly, exploring therapies for highly conserved
proteins such as PRPF8 can harness the large progeny and
short lifespan of lower organisms that allows high-throughput
drug or genetic screening (Kukhtar et al., 2020). In view of
our findings, the mutated PRPF8 allele-specific therapeutics
would be the most effective approach. This, strategy, however,
would be efficient if applied very early in the disease
before other affected splicing proteins compromise the main
cellular functions.
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